日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trial

在III期NeoALTTO试验中,HER2/CEP17比值与HER2靶向新辅助治疗后的pCR相关。

Singer, Christian F; Koenig, Franz; Kacerovsky-Strobl, Stephanie; Danzinger, Sabine; Brunner, Christine; Suppan, Christoph; Deutschmann, Christine; Balic, Marija; Greil, Richard; Egle, Daniel; de Azambuja, Evandro; Di Cosimo, Serena; Choudhury, Anup; Gnant, Michael

Association between body mass index and risk of breast cancer according to breast cancer subtypes: A systematic review and meta-analysis

根据乳腺癌亚型分析体重指数与乳腺癌风险的关联:一项系统评价和荟萃分析

Dauccia, Chiara; Bruzzone, Marco; Arecco, Luca; Blondeaux, Eva; Sirico, Marianna; Gerosa, Riccardo; Franzoi, Maria Alice; Brandão, Mariana; Perrone, Lorenzo; Pedrazzoli, Paolo; Desmedt, Christine; Di Cosimo, Serena; Vernieri, Claudio; Collet, Laetitia; Lambertini, Matteo; de Azambuja, Evandro; Agostinetto, Elisa

Health-related quality of life and fear of recurrence after early breast cancer treatment: Results from a cross-sectional survey

早期乳腺癌治疗后健康相关生活质量和复发恐惧:一项横断面调查的结果

Mosconi, Paola; Folli, Secondo; Miceli, Rosalba; Scrudato, Serena; Gennaro, Massimiliano; Tinè, Gabriele; De Santis, Maria Carmen; Ferraris, Cristina; Martelli, Gabriele; Di Carlo, Immacolata; Maugeri, Ilaria; Arata, Alessio; Carnevale, Maria Grazia; Listorti, Chiara; Agresti, Roberto; Borreani, Claudia; Vernieri, Claudio; Pruneri, Giancarlo; Baili, Paolo; Appierto, Valentina; Di Cosimo, Serena; Apolone, Giovanni

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)

新辅助治疗期间残余病灶(RD)生物学和基因表达变化对HER2阳性早期乳腺癌(EBC)患者的预后价值

Fernandez-Martinez, A; Tanioka, M; Ahn, S G; Zagami, P; Pascual, T; Rediti, M; Tang, G; Hoadley, K A; Venet, D; Rashid, N U; Spears, P A; Di Cosimo, S; de Azambuja, E; Choudhury, A; Rastogi, P; Islam, M N; Cortes, J; Llombart-Cussac, A; Swain, S M; Sotiriou, C; Prat, A; Perou, C M; Carey, L A

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial

在PARSIFAL试验中,对帕博西尼联合氟维司群或来曲唑治疗内分泌敏感、激素受体阳性/HER2阴性晚期乳腺癌患者进行了延长随访。

Llombart-Cussac, A; Pérez-García, J M; Bellet, M; Dalenc, F; Gil-Gil, M; Ruiz-Borrego, M; Gavila, J; Schmid, P; Zamora, P; Wheatley, D; Martínez-de Dueñas, E; Amillano, K; Di Cosimo, S; Anton, A; Cottu, P; Shimizu, E; Fernandez, M; Sampayo-Cordero, M; Cortés, J

Reply to the letter: What can paintings teach us?

回复信:绘画能教会我们什么?

Di Cosimo, Serena; Perciaccante, Antonio; Donell, Simon T; Wimmer, Judith; Nerlich, Andreas G; DeWaal, Johann C; Cortesi, Laura; Bianucci, Raffaella

Towards precision therapy in HER2-positive early-stage breast cancer

迈向HER2阳性早期乳腺癌的精准治疗

Di Cosimo, Serena; Verderio, Paolo

Treatment of oligometastatic breast cancer: The role of patient selection

寡转移性乳腺癌的治疗:患者选择的作用

Colciago, Riccardo Ray; De Santis, Maria Carmen; Giandini, Carlotta; Carnevale, Maria Grazia; Di Cosimo, Serena

Advancing breast cancer therapy in the era of molecular diagnostics

在分子诊断时代推进乳腺癌治疗

Carnevale, Maria Grazia; Colciago, Riccardo Ray; De Santis, Maria Carmen; Cortesi, Laura; De Marco, Cinzia; Marra, Antonio; Vingiani, Andrea; Nolè, Franco; Curigliano, Giuseppe; Pruneri, Giancarlo; Llombart-Cussac, Antonio; Di Cosimo, Serena; Cortes, Javier

HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy

HER2低表达乳腺癌属于免疫冷癌:肿瘤浸润免疫细胞的深入研究及其对免疫疗法的意义

Pizzamiglio, S; Blanda, A; Appierto, V; Minicozzi, P; Carnevale, M G; De Santis, M C; Re, B; Cortesi, L; Gasparini, E; Arpino, G; Giuliano, M; Molinaro, V; Iorio, M V; De Cecco, L; Bertolotti, A; Brich, S; Vingiani, Andrea; De Marco, C; Pruneri, G; Verderio, P; Di Cosimo, S